NCT01579994 - Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2012

Primary Completion Date

December 28, 2020

Study Completion Date

December 28, 2020

Conditions

Advanced Lung Cancer

Interventions

DRUG

Ganetespib (STA-9090) and crizotinib

Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER